Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has submitted to the exchange a statement of deviation(s) or variation(s) in the use of proceeds from a prior issue, as required under Regulation 32 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations. Regulation 32 filings are mandatory for companies that have raised funds through a public, rights, or preferential issue, and they must report any change in how the money is being used compared to the original plan. The specific details of the deviation, including the amount involved and the revised use of funds, were not disclosed in the headline. Investors should refer to the full filing on the NSE/BSE portal for the exact numbers and reasons behind the variation.
Deviation filings are routine but can be a red flag if they signal a major shift in the originally stated purpose of fundraising, potentially affecting investor confidence. Shareholders should review the detailed statement to assess whether the change in use of proceeds is justified and in the company's interest.